Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study-Reference-Cited by-同舟云学术

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Published:2020-08 Issue:8 Volume:31 Page:1056-1064
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mok T.,Camidge D.R.,Gadgeel S.M.,Rosell R.,Dziadziuszko R.,Kim D.-W.,Pérol M.,Ou S.-H.I.,Ahn J.S.,Shaw A.T.,Bordogna W.,Smoljanović V.,Hilton M.,Ruf T.,Noé J.,Peters S.

Funder

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference12 articles.

1. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer;Yuan;Signal Transduct Target Ther,2019

2. What it takes to improve a first-generation inhibitor to a second- or third-generation small molecule;Rodon Ahnert;Am Soc Clin Oncol Educ Book,2019

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

4. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017

5. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small-cell lung cancer in the global phase III ALEX study;Camidge;J Thorac Oncol,2019

Cited by 407 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Induced SJS/TEN: A Case Report and a Review;TURK ONCOL DERG;2024

2. Comparative analysis of transcriptomic and proteomic expression between two non-small cell lung cancer subtypes;2024-09-10

3. New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years;Journal of Clinical Oncology;2024-09-04

4. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer;Lung Cancer;2024-09

5. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09